Monthly Archives: February 2019
P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY
The endothelial adhesion protein mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is a promising novel drug target. The fully human IgG2 anti-MAdCAM-1 monoclonal antibody SHP647 is in development for the treatment of Crohn’s disease (CD). Continue reading
P038 NETWORK META-ANALYSIS: COMPARATIVE EFFICACY OF BIOLOGICS IN THE TREATMENT OF BIOLOGIC-NAïVE JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
There are several biologic therapies approved in Japan for moderate-to-severe ulcerative colitis (UC) but there are no head-to-head randomized controlled trials (RCTs) or network meta-analysis (NMA) for comparing their efficacy. We aimed to compare the… Continue reading
P039 REINVENTING INFLAMMATORY BOWEL DISEASE (IBD) CLINICAL TRIAL RECRUITMENT USING NOVEL DIGITAL MEDICINE TOOLS
Issues with patient recruitment and enrollment are the primary barriers for missed clinical trial timelines; 8 out of 10 clinical trials are delayed or unable to be completed because of lack of timely patient recruitment. Current patient recruitment ef… Continue reading
P040 TEXT MESSAGE-BASED TELEMEDICINE DOES NOT IMPROVE QUALITY OF LIFE OR DEPRESSIVE SYMPTOMS IN IBD PATIENTS
Inflammatory bowel disease (IBD) is a chronic debilitating condition involving the gastrointestinal (GI) tract that has a negative impact on quality of life (QoL). Depressive symptoms (DS) are common in affected patients and contribute to decreased QoL… Continue reading
P041 THE GUT-SELECTIVE, ORALLY ADMINISTERED, PAN-JAK INHIBITOR TD-1473 DEMONSTRATES FAVORABLE SAFETY, TOLERABILITY, PHARMACOKINETIC, AND SIGNAL FOR CLINICAL ACTIVITY IN SUBJECTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
A need exists for effective and safe oral therapeutic options for moderate to severe ulcerative colitis (UC). TD-1473 is an orally administered and gut-selective pan-Janus kinase (JAK) inhibitor that was well tolerated by healthy volunteers when admini… Continue reading
P042 INTRACOLONIC BIFIDOBACTERIUM APPLICATION CAN PROVIDE MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE
Several alterations (dysbiosis) have been found in the gut microbial profile of UC patients including a decrease in diversity, Bifidobacterium and other some of commensal gut flora. Despite the impressive alterations in the gut microbiome of UC patient… Continue reading
P043 OUTCOME OF THE REPETITIVE FECAL MICROBIOTA TRANSPLANTATION USING FECAL SOLUTION PREPARED UNDER THE ANAEROBIC CONDITION FOLLOWING THE ANTIBIOTIC PRETREATMENT IN EIGHT CHILDREN WITH ULCERATIVE COLITIS
Fecal Microbiota Transplantation (FMT) is effective for the treatment of recurrent Clostridium difficile infection, but its efficacy for ulcerative colitis (UC) remains controversial. Ishikawa, et al reported that combination therapy with FMT and anti… Continue reading
01 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB IS MORE COMMON THAN STANDARD DOSING IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE
DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease [CD]: 4122, ulcerative colitis [UC]: 1643, and IBD-unclassifie… Continue reading
P044 EFFICACY OF INDUCTION THERAPY WITH HIGH-INTENSITY TOFACITINIB IN 4 PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
Acute severe ulcerative colitis (ASUC) is a serious presentation of ulcerative colitis (UC) that carries a high risk for medical failure. First line therapy relies on IV corticosteroids, however up to 30% of patients will not respond. Even when second … Continue reading
P045 IS THE USE OF THIOPURINES WANING? INTERCONTINENTAL TRENDS REVEALED BY THE DEVELOP REGISTRY
Thiopurines (TP) have been a historical mainstay in the treatment of pediatric IBD since the 1990s. However, the advent of anti-TNF therapy and increasing concerns about long-term safety of TP has prompted some clinicians to re-evaluate their role. DEV… Continue reading